Aims The aim of this study was to examine the effects of bisoprolol (BIS), a selective b 1 -adrenoceptor antagonist without partial agonistic activity, on noradrenaline-and phenylephrine-evoked venoconstriction in man using the dorsal hand vein compliance technique. Methods Twelve healthy male volunteers participated in three weekly experimental sessions. Subjects were allocated to treatments and sessions on a double-blind basis. In each session either BIS 5 mg (BIS5), or BIS 10 mg (BIS10), or placebo was administered orally, and noradrenaline acid tartrate (0.1-33.33 ng min −1 ) followed by phenylephrine hydrochloride (0.033-10 mg min −1 ) was infused into the dorsal hand vein. Systolic and diastolic blood pressure and heart rate were also measured.
Introduction practolol, a selective b 1 -adrenoceptor antagonist, could be used as an argument in favour of the existence of venodilator Like other superficial veins [1] [2] [3] , the dorsal hand vein in man contains both b-and a-adrenoceptors [4-6]. There is b 1 -adrenoceptors in the dorsal hand vein which could be activated by noradrenaline. Atenolol, a selective b 1 -adrenoevidence that b 2 -adrenoceptors mediate venodilatation [1, 6] , and both a 1 -and a 2 -adrenoceptors mediate venoconstricceptor antagonist, has been reported to be without any effect on phenylephrine-evoked venoconstriction [11] , indition [6, 7] . The effects of b-adrenoceptor antagonists have been studied on both isoprenaline-evoked venodilatation cating the lack of involvement of b 1 -adrenoceptors in the venoconstrictor response to phenylephrine. On the other and on noradrenaline-and phenylephrine-evoked venoconstriction. It is well documented that isoprenaline-evoked hand, nebivolol, another selective b 1 -adrenoceptor antagonist, has been shown to be effective in antagonizing venodilatation is antagonized by b-adrenoceptor antagonists such as propranolol [4, 8, 9] , consistent with the interaction phenylephrine-evoked venoconstriction [11, 12] . This latter observation has been shown to be due to the release of of both the agonist and the antagonist with b-adrenoceptors. The effects of b-adrenoceptor antagonists on noradrenalinenitric oxide from the vascular endothelium by nebivolol [11, 12] . and phenylephrine-evoked venoconstrictor responses are more controversial. Thus it has been reported that the
In the present study we examined the effects of two oral doses of bisoprolol (BIS), a highly selective b 1 -adrenoceptor venoconstrictor response to noradrenaline can be potentiated by both propranolol and practolol [4, 10] . This observation antagonist [13, 14] , on constrictor responses to the a 1 -adrenoceptor agonists noradrenaline and phenylhas been interpreted as evidence for the blockade of venodilator b-adrenoceptors which attenuate the constrictor ephrine, using the dorsal hand vein compliance technique [15] in healthy volunteers. Some of these results have been communicated to the British Pharmacological pressure and pulse rate were monitored at frequent intervals Methods (see below) on the contralateral arm.
Ethical considerations Cardiovascular measures
Systolic and diastolic blood pressure were measured using a mercury sphygmomanometer, and The study protocol was approved by the University of Nottingham Medical School Ethics Committee. All volunheart rate by feeling the pulse of the radial artery at the wrist for 1 min. All measurements were taken on the arm teers gave their written informed consent following a verbal explanation of the study and after reading a detailed opposite to the one used for the pharmacological testing, before and after treatment with the systemically administered information sheet.
and locally infused drugs; the pre-post treatment change was taken as the effect of the drug. Subjects
The study was conducted in 12 healthy male volunteers
Experimental design aged 18-28 years (mean±s.d., 21.3±3.2 years), body weight 62-85 kg (mean±s.d., 71.1±5.9 kg). Each subject Each volunteer participated in three experimental sessions at weekly intervals, each session being associated with one of completed a brief medical history and underwent a complete physical examination. Subjects had not participated in drug the following treatments: BIS5, BIS10, or placebo. Subjects were randomly allocated to treatments and sessions according studies within 3 months before the start of the present study, and had not used any drug within the 14 days preceding to a double-blind balanced design. Throughout the session, the subject rested in the supine position. After an initial the study. They were requested to stop smoking and to avoid drinking alcohol, coffee and other caffeine-containing period of adaptation to laboratory conditions (30 min), pretreatment measurements of heart rate and blood pressure beverages for at least 12 h before each experimental session. All subjects were advised to have a light meal 2 h before were performed. Oral study medication (BIS5, BIS10 or placebo) was then administered. 120 min later, baseline the experimental sessions. All subjects indicated compliance with these requests.
measurements of venous diameter were made over a period of 30 min or until two consecutive approximately equal (i.e. within 5% of each other) readings were obtained. After Drugs the baseline venous diameter had been recorded, the local infusion of six doses of the agonists, first noradrenaline and Noradrenaline acid tartrate (LevophedA) was obtained from Sanofi-Winthrop, Guildford, Surrey, UK, phenylephrine then phenylephrine, commenced; each dose was applied for 5-7 min. Heart rate, and systolic and diastolic blood pressure hydrochloride (Phenylephrine InjectionA) from Boots Pharmaceuticals, Nottingham, UK, bisoprolol fumarate measurements were carried out on six occasions in each session: before and 2 h after the ingestion of the capsule, (Monocor 5A, Monocor 10A) from Lic. E. Merck, Darmstadt, Germany. The sterile solutions of noradrenaline before the infusion of noradrenaline and after the infusion of the highest dose of noradrenaline, before the infusion of acid tartrate and phenylephrine hydrochloride were administered locally into the vein at a constant rate of 0.3 ml min −1 phenylephrine and after the infusion of the highest dose of phenylephrine. The timing of start of the local infusion and and over the following dose ranges: noradrenaline acid tartrate 0.1-33 ng min −1 ; phenylephrine hydrochloride post-treatment tests was based on the single-dose pharmacokinetics of BIS: it had been reported that peak plasma 0.033-10 mg min . BIS (5 and 10 mg) and lactose placebo were prepared in identical capsules for double-blind oral concentration is attained 2-4 h after oral administration of a single dose [18, 19] . administration.
Data analysis Tests The dorsal hand vein compliance technique The dorsal hand
Dorsal hand vein responses The data obtained with the two locally infused agonists were analyzed separately. The raw vein compliance technique, as modified by Aellig [15] , was used as described previously [17] . Each period of drugdata were analyzed with two-way analysis of variance (dose of agonist; systemic drug treatment) with repeated measures infusion consisted of an initial 3 min period with the cuff deflated, followed by a further 2-4 min period with the cuff on both factors. When a significant overall main effect of drug treatment was identified, individual comparisons were inflated (i.e. a sufficient period of time to ensure that the signal from the linear variable differential transformer had made between placebo and each dose of BIS with Dunnett's test. The individual dose-response curves obtained in each reached plateau). Increasing concentrations of the agonist were given at a constant infusion rate (0.3 ml min −1 ). A subject were also analyzed to estimate the maximal response (E max ) and the dose producing the half-maximal response washout period of 15 min was allowed between the infusions of the highest dose of noradrenaline and the first dose of (ED 50 ), using a computer programme based on Wilkinson's method [20] . This analysis also provided the index of phenylephrine by switching to a separate infusion pump connected to the system. In each experiment, vein size determination (p 2 ) for each curve; p 2 expresses the proportion of the data variance accounted for by the fitted returned to baseline during the washout period (see Results). The entire period of infusion was 2.0-2.5 h; pilot experifunction [21] . The distribution of the ED 50 values was normalized by logarithmic transformation, and the geometric ments had indicated that there was no detectable loss of potency of either agonist over periods of up to 4 h. Blood mean was calculated for each of the six dose-response curves (i.e. noradrenaline/placebo, noradrenaline/BIS5, noradrenaline/BIS10, phenylephrine/placebo, phenylephrine/BIS5, phenylephrine/BIS10 
Results

Dorsal hand vein responses
Venous diameter was recorded prior to the application of n=12. 100% response was defined as abolition of the venodilatation produced by the inflation of the cuff.
Effects of agonists
The dose-response curve to noradrenaline in the presence Interactions between agonists and bisoprolol of placebo is shown in Figure 1 , and the dose-response curve to phenylephrine in the presence of placebo is shown Noradrenaline Figure 1 shows the dose-response curves to noradrenaline in the presence of placebo and BIS 5 and in Figure 2 . In the case of the individually fitted curves (n= 12), the proportion of the data variance accounted for by 10 mg. BIS shifted the noradrenaline dose-response curves to the right. ANOVA showed significant main effects of the fitted function (p 2 ) ranged from 0.83 to 0. In the case of the individually fitted curves (n=12), the value of p 2 ranged from 0.91 to geometric mean ED 50 for phenylephrine, and the potency ratio (noradrenaline/phenylephrine) was 42.
0.99 (median 0.97) in the presence of BIS5, and from 0.92 Table 1 Venous diameter (mm; mean±s.e. mean, n=12) at a congestion pressure of 45 mmHg, 2 h after the ingestion of placebo (Pl), bisoprolol 5 mg (BIS5) and bisoprolol 10 mg (BIS10), and prior to the local infusion of the agonists noradrenaline (NA) and phenylephrine (PHE). Right-hand columns show mean differences (95% CI) between each dose of BIS and Pl. Figure 3 . A repeated-measures analysis of variance of the log ED 50 data showed a significant main effect of the systemic treatment condition ( F(2,22)= 9.88, P<0.0025); analysis of variance of the E max data showed no significant effect of treatment condition (F<1). Figure 3 ) was increased by 155% and 289% in the presence of BIS5 and BIS10, respectively, and the dose ratios were 2.55 for placebo/BIS5, and 3.89 for placebo/BIS10.
Cardiovascular measures
Phenylephrine dose (µgmin Figure 3 ) was increased by 111% and 233% in the presence venoconstrictor both in the human dorsal hand vein [6] and in the human isolated femoral vein [22] . of BIS5 and BIS10, respectively, and the dose ratios were 2.11 for placebo/BIS5, and 3.33 for placebo/BIS10.
Both oral doses (5 and 10 mg) of BIS could antagonize the venoconstrictor responses to noradrenaline and phenylephrine leading to rightward shifts in the dose-response Phenylephrine Figure 2 shows the dose-response curves to phenylephrine in the presence of placebo and BIS5 and curves and increases in the values of ED 50 . The antagonism was dose dependent. This was a surprising finding since the BIS10. It is apparent that there were rightward shifts in the curves in the presence of BIS. ANOVA showed a significant venoconstrictor responses are known to be mediated by the activation of a-adrenoceptors: noradrenaline can effect of both dose of phenylephrine ( F(5,55) 
Table 2
Parameters of dose-response curves: differences (mean, 95% CI) between placebo (Pl) and bisoprolol 5 mg (BIS5), and bisoprolol 10 mg (BIS10). phenylephrine is a selective a 1 -adrenoceptor agonist. It is can antagonzie a 1 -adrenoceptor mediated venoconstrictor responses [23] [24] [25] [26] [27] . However, BIS is a highly selective b 1 -known that some b-adrenoceptor antagonists such as labetalol and carvedilol have affinity for a 1 -adrenoceptors and thus adrenoceptor antagonist with no affinity for either a 1 -or a 2 -adrenoceptors [13, 14] , and thus an interaction with a 1 -documented [38, 39] , the possible involvement of b 1 -adrenoceptors in mediating venodilator effects is more adrenoceptors cannot explain the present observations.
Another possible mechanism to be considered is a partial controversial [4, 11] . In an early study White & Udwadia [4] reported that both the non-selective b 1 /b 2 -adrenoceptor agonistic activity of BIS at b 2 -adrenoceptors (the so called intrinsic sympathomimetic activity, 'ISA'), which has been antagonist propranolol and the selective b 1 -adrenoceptor antagonist practolol can potentiate the constrictor response shown to be the characteristic of some b-adrenoceptor antagonists, for example oxprenolol [10] . The operation of of the dorsal hand vein to noradrenaline. This observation can be interpreted as evidence for the blockade of masked such a mechanism would lead to functional antagonism between a-adrenoceptor mediated vasoconstriction and b 2 -venodilator b-adrenoceptors by the antagonists resulting in an increase in the size of the constrictor response [40] . The adrenoceptor mediated vasodilatation. In the case of functional antagonism two agonists act at two receptor systems effectiveness of practolol would suggest that b 1 -adrenoceptors are involved in mediating the venodilator effect of noradremediating opposite effects via the same effector system. This drug-receptor interaction can lead to a shift in the dosenaline. The potentiation of the constrictor responses to noradrenaline by practolol is a surprising finding since response curve to one of the agonists in the presence of the other agonist which is indistinguishable from competitive practolol has pronounced partial agonistic activity [31] which is expected to lead to venodilatation which in turn could antagonism [28, 29] . However, again, there is no evidence indicating that BIS has any agonistic activity at either b 1 -or counteract the potentiation of the venoconstriction resulting from b 1 -adrenoceptor blockade. Furthermore, if noradrenab 2 -adrenoceptors [13, 14] .
Therefore it is unlikely that the antagonism of the line activated masked inhibitory b 1 -adrenoceptors, we would have expected that in our experiment the response to venoconstrictor responses to noradrenaline and phenylephrine by BIS is due to an interaction at adrenoceptors. A noradrenaline would have been potentiated whereas the response to phenylephrine, which has little affinity for further possibility is that the b-adrenoceptor antagonist might have caused venodilatation by a direct smooth muscle b-adrenoceptors, would have remained unaffected. However, as responses to both noradrenaline and phenylephrine were relaxant effect. Although it has been shown that some b-adrenoceptor antagonists (e.g. SK&F 92657) may have antagonized by BIS, we are unable to confirm the existence of venodilator b 1 -adrenoceptors in the dorsal hand vein. In some such hydralazine-like effect in the dorsal hand vein [30] , there is evidence against such an action of BIS [31] .
this respect it would be of interest to examine the effects of atenolol, another selective b 1 -adrenoceptor antagonist, on It is of interest to consider the possibility that an endothelium-related mechanism is involved in the antagonvenoconstrictor responses to noradrenaline in the human dorsal hand vein since it has been shown that this drug has istic effects of BIS. Indeed it has been reported recently that the selective b 1 -adrenoceptor antagonist nebivolol can dilate no effect on venoconstrictor responses to phenylephrine [11] . the human dorsal hand vein [11] due to its ability to release nitric oxide from vascular endothelium [11, 12] . It remains AHA is supported by a Scholarship from Al-Arab Medical to be shown whether the same mechanism operates in the University of Benghazi, Libya. case of BIS. Furthermore, it has been reported that chronic administration of BIS leads to the inhibition of the synthesis References of the venoconstrictive substance endothelin-1 [32]. However, it is unlikely that an effect on endothelin-1 unlikely that a reduction in systemic arterial blood pressure b-adrenoceptor antagonist which also lowers systemic blood
In vivo studies on alpha-adrenergic subtypes in human veins.
pressure, has no effect on the diameter of the dorsal hand the existence of venodilator b 2 -adrenoceptors is well
